Industry Insights

  1. Key Considerations In Early-Stage Biopharma Financing 5/11/2022

    After over two years of soaring IPO valuations and high stock prices, biotech had a reckoning in the back half of 2021. But while the industry is clearly facing headwinds, there’s significant cause for optimism for early-stage biotechs looking for funding, not the least of which is 2021’s high levels of venture capital fund formation.

  2. Why Russia's Invasion Of Ukraine Threatens Our Life Science Ecosystem 6/22/2022

    I posit that only pluralistic democracies committed to the rule of law can support the kind of investment and innovation our industry requires to thrive, while autocracies can’t make the same claim.

  3. 6 Key Questions When Selecting Your Cell Banking Manufacturing Partner 5/8/2024

    Evaluating a potential cell banking partner's experience, testing capabilities, and approach to material management can help guarantee the quality and consistency of your therapeutic cells.

  4. The Benefits Of Streamlining And Standardizing Plasmid DNA 11/29/2021

    The need for greater volumes of high-quality raw materials like plasmid DNA in the cell and gene therapy space has made pDNA standardization integral to streamlining the development process.

  5. Partnering At Every Stage: Providing Capable Capacity For Manufacturing

    Finding a CDMO partner with the requisite expertise, materials, external supply chain, and capacity is key to maximizing a therapy’s chances of commercial success.

  6. Pharma 4.0 And Digitalization Strategies For Drug Manufacturing 7/11/2025

    Explore a modular approach to Pharma 4.0 that empowers organizations to embrace digital transformation at their own pace and is tailored to their unique needs.

  7. The Future Looks Promising For CAR T-Cell Therapy 6/20/2023

    This article shares new market research for CAR T-cell therapies. The U.S. leads the market, but there is positive movement in Europe and other areas of the world.

  8. Cell Therapy: Process Design Considerations To Support Commercialization 3/28/2017

    Cell therapies have the potential to revolutionize the biopharmaceutical world, but today’s processes, logistics, and delivery make for a challenging entry into the sector’s growth curve. As the industry evolves, we have to answer (at least) three important questions when bringing these exciting new therapies to market.

  9. The Power Of The Pool: Using Bulk Cultures For Clinical Trial Manufacturing 7/29/2024

    Stable bulk cultures, made highly uniform using transposase-mediated technologies, may be the key to expediting clone selection for many biopharmaceutical applications.

  10. MES Is Still In The CD ROM Era But The Data Architecture Has Moved On 2/20/2026

    Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.